139 related articles for article (PubMed ID: 35880695)
1. Exploration of the breast ductal carcinoma in situ signature and its prognostic implications.
Zhang J; Lin H; Hou L; Xiao H; Gong X; Guo X; Cao X; Liu Z
Cancer Med; 2023 Feb; 12(3):3758-3772. PubMed ID: 35880695
[TBL] [Abstract][Full Text] [Related]
2. Abnormal expression of Nek2 and β-catenin in breast carcinoma: clinicopathological correlations.
Wang S; Li W; Lv S; Wang Y; Liu Z; Zhang J; Liu T; Niu Y
Histopathology; 2011 Oct; 59(4):631-42. PubMed ID: 22014044
[TBL] [Abstract][Full Text] [Related]
3. Serum autoantibody signature of ductal carcinoma in situ progression to invasive breast cancer.
Mangé A; Lacombe J; Bascoul-Mollevi C; Jarlier M; Lamy PJ; Rouanet P; Maudelonde T; Solassol J
Clin Cancer Res; 2012 Apr; 18(7):1992-2000. PubMed ID: 22322670
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive analysis of the 21-gene recurrence score in invasive ductal breast carcinoma with or without ductal carcinoma in situ component.
Zeng Y; Gao W; Chen X; Shen K
Br J Cancer; 2021 Mar; 124(5):975-981. PubMed ID: 33335279
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA Expression Profile in Early-Stage Breast Cancers.
Patel K; Rao DM; Sundersingh S; Velusami S; Rajkumar T; Nair B; Pandey A; Chatterjee A; Mani S; Gowda H
Microrna; 2024; 13(1):71-81. PubMed ID: 37873952
[TBL] [Abstract][Full Text] [Related]
6. Identification of latent biomarkers in connection with progression and prognosis in oral cancer by comprehensive bioinformatics analysis.
Reyimu A; Chen Y; Song X; Zhou W; Dai J; Jiang F
World J Surg Oncol; 2021 Aug; 19(1):240. PubMed ID: 34384424
[TBL] [Abstract][Full Text] [Related]
7. Whole-Exome Sequencing Analysis of the Progression from Non-Low-Grade Ductal Carcinoma
Pareja F; Brown DN; Lee JY; Da Cruz Paula A; Selenica P; Bi R; Geyer FC; Gazzo A; da Silva EM; Vahdatinia M; Stylianou AA; Ferrando L; Wen HY; Hicks JB; Weigelt B; Reis-Filho JS
Clin Cancer Res; 2020 Jul; 26(14):3682-3693. PubMed ID: 32220886
[TBL] [Abstract][Full Text] [Related]
8. Identification of biomarkers associated with diagnosis and prognosis of colorectal cancer patients based on integrated bioinformatics analysis.
Chen L; Lu D; Sun K; Xu Y; Hu P; Li X; Xu F
Gene; 2019 Apr; 692():119-125. PubMed ID: 30654001
[TBL] [Abstract][Full Text] [Related]
9. Does concomitant ductal carcinoma in situ affect the clinical outcome in breast cancer patients with invasive ductal carcinoma: An Asian perspective.
Lee WP; Shetty SS; Seah CMJ; Tan PT; Tan SM
Cancer Rep (Hoboken); 2022 Sep; 5(9):e1646. PubMed ID: 35892151
[TBL] [Abstract][Full Text] [Related]
10. Invasive ductal carcinoma with coexisting ductal carcinoma in situ (IDC/DCIS) versus pure invasive ductal carcinoma (IDC): a comparison of clinicopathological characteristics, molecular subtypes, and clinical outcomes.
Goh CW; Wu J; Ding S; Lin C; Chen X; Huang O; Chen W; Li Y; Shen K; Zhu L
J Cancer Res Clin Oncol; 2019 Jul; 145(7):1877-1886. PubMed ID: 31089799
[TBL] [Abstract][Full Text] [Related]
11. Analysis of stromal signatures in the tumor microenvironment of ductal carcinoma in situ.
Sharma M; Beck AH; Webster JA; Espinosa I; Montgomery K; Varma S; van de Rijn M; Jensen KC; West RB
Breast Cancer Res Treat; 2010 Sep; 123(2):397-404. PubMed ID: 19949854
[TBL] [Abstract][Full Text] [Related]
12. Expression profiling of in vivo ductal carcinoma in situ progression models identified B cell lymphoma-9 as a molecular driver of breast cancer invasion.
Elsarraj HS; Hong Y; Valdez KE; Michaels W; Hook M; Smith WP; Chien J; Herschkowitz JI; Troester MA; Beck M; Inciardi M; Gatewood J; May L; Cusick T; McGinness M; Ricci L; Fan F; Tawfik O; Marks JR; Knapp JR; Yeh HW; Thomas P; Carrasco DR; Fields TA; Godwin AK; Behbod F
Breast Cancer Res; 2015 Sep; 17():128. PubMed ID: 26384318
[TBL] [Abstract][Full Text] [Related]
13. Accompanying DCIS in breast cancer patients with invasive ductal carcinoma is predictive of improved local recurrence-free survival.
Dieterich M; Hartwig F; Stubert J; Klöcking S; Kundt G; Stengel B; Reimer T; Gerber B
Breast; 2014 Aug; 23(4):346-51. PubMed ID: 24559611
[TBL] [Abstract][Full Text] [Related]
14. Comparison of HER2 amplification status among breast cancer subgroups offers new insights in pathways of breast cancer progression.
Lambein K; Van Bockstal M; Vandemaele L; Van den Broecke R; Cocquyt V; Geenen S; Denys H; Libbrecht L
Virchows Arch; 2017 Nov; 471(5):575-587. PubMed ID: 28567637
[TBL] [Abstract][Full Text] [Related]
15. Sharp Downregulation of Hub Genes Associated With the Pathogenesis of Breast Cancer From Ductal Carcinoma
Wang Y; Liang F; Zhou Y; Qiu J; Lv Q; Du Z
Front Oncol; 2021; 11():634569. PubMed ID: 34094915
[TBL] [Abstract][Full Text] [Related]
16. PIK3CA mutations in ductal carcinoma in situ and adjacent invasive breast cancer.
Agahozo MC; Sieuwerts AM; Doebar SC; Verhoef EI; Beaufort CM; Ruigrok-Ritstier K; de Weerd V; Sleddens HFBM; Dinjens WNM; Martens JWM; van Deurzen CHM
Endocr Relat Cancer; 2019 May; 26(5):471-482. PubMed ID: 30844755
[TBL] [Abstract][Full Text] [Related]
17. Identification and transfer of spatial transcriptomics signatures for cancer diagnosis.
Yoosuf N; Navarro JF; Salmén F; Ståhl PL; Daub CO
Breast Cancer Res; 2020 Jan; 22(1):6. PubMed ID: 31931856
[TBL] [Abstract][Full Text] [Related]
18. The prognostic role of HER2 expression in ductal breast carcinoma in situ (DCIS); a population-based cohort study.
Borgquist S; Zhou W; Jirström K; Amini RM; Sollie T; Sørlie T; Blomqvist C; Butt S; Wärnberg F
BMC Cancer; 2015 Jun; 15():468. PubMed ID: 26062614
[TBL] [Abstract][Full Text] [Related]
19. Grade of ductal carcinoma in situ accompanying infiltrating ductal carcinoma as an independent prognostic factor.
Kim JY; Han W; Moon HG; Park IA; Ahn SK; Kim J; Lee JW; Kim T; Kim MK; Noh DY
Clin Breast Cancer; 2013 Oct; 13(5):385-91. PubMed ID: 23870857
[TBL] [Abstract][Full Text] [Related]
20. Influence of ductal carcinoma in situ on the outcome of invasive breast cancer. A prospective cohort study.
Lopez Gordo S; Blanch Falp J; Lopez-Gordo E; Just Roig E; Encinas Mendez J; Seco Calvo J
Int J Surg; 2019 Mar; 63():98-106. PubMed ID: 30738200
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
